The healthcare data producer raised $19m from investors including Johnson & Johnson for a round already including Amgen, McKesson, Horizon Health Services, Sanofi and UCB Pharma.

Ci:z Investment led a round also backed by CareNet that advanced the total raised by the spinal disease drug developer to more than $70m.

Salesforce Ventures contributed to an $11.5m round that will fund the addition of more features to Acto's mobile drug information platform.

Cancer and fibrosis therapy developer Forbius has agreed to be acquired by Bristol Myers Squibb nine years after it was spun off by YM BioSciences.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

AI pathology aid developer Medmain, a Kyushu Universty-aligned startup, will use the capital to support international expansion.

Medical equipment maker Yuanzhi Technology led a $43.5m round that will fund work on BGI-backed YuceBio's TMB biomarker.

Toronto Innovation Acceleration Partners has scored an exit having invested at least twice in cancer and fibrosis therapy developer Forbius.

Novartis and existing investors GV, Kaiser Permanente Ventures and Roche Venture Fund helped the cancer test developer push its total funding past the $500m mark.

The Teva, Allianz and Takeda-backed telehealth technology producer has filed to raise up to $100m in an offering that will be boosted by another $100m from Google.